Camelot Ventures leads Series B funding of Cellerant
SAN CARLOS, California — September 22, 2005 -- Cellerant Therapeutics, Inc. today announced that it has raised $9 million in a second closing of its Series B round, bringing the total to $25 million. The first closing was led by Novel Bioventures, with the participation of Series A stockholders MPM Capital, Allen & Company LLC, and BD Ventures, and new investors CX Venture Group and Amgen founder George Rathmann. Participants in this second closing include Camelot Ventures, George Rathmann and Eminent Venture Capital Corp. "Cellerant is extremely pleased with this second closing of the Series B and the addition of Camelot Ventures and Eminent Venture Capital Corp. to our investor group," said Bruce Cohen, President and Chief Executive Officer of Cellerant. "Since the first close of our Series B, Cellerant has made significant progress in advancing our purified hematopoietic stem cell infusion, CLT-001, toward the clinic for sickle cell disease. We expect that trial to be under way early next year. This Series B funding will allow us to advance the CLT-001 sickle cell program as well as CLT-001 for the treatment of autoimmune diseases and our cell-based product CLT- 008 for the treatment of radiation- and chemotherapy-induced neutropenia."
About Camelot Ventures
About Cellerant Therapeutics